Company intelligence / Profile preview
LiteVax BV
Ophemert, Netherlands
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
LiteVax BV develops novel human vaccine adjuvants that outperform current alternatives by providing higher efficacy with minimal toxicity. Their lead candidate enables lower-cost production and effective single-dose applications. The company’s main program has entered its second clinical trial as of February 2024, targeting improved influenza vaccination in the elderly population.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Vaccine adjuvants (synthetic carbohydrate and polymer-based)Nanofiber technology for transmucosal deliveryImmunogenic vaccines (e.g., HER2 vaccine)
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Request access →03
Partnerships
INDIGO consortium partners from EU, India, USAdaptVacExpreS^ion BiotechnologiesProxi BiotechCellVaxINRAEImmunoPrecise AntibodiesIRTAmultiple public/private R&D organizations via EU projects.
Beyond the preview
Go deeper on LiteVax BV.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LiteVax BV.